A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019

{ 'indexed': {'date-parts': [[2022, 8, 29]], 'date-time': '2022-08-29T17:11:23Z', 'timestamp': 1661793083248}, 'reference-count': 39, 'publisher': 'Oxford University Press (OUP)', 'issue': '8', 'license': [ { 'start': { 'date-parts': [[2022, 8, 8]], 'date-time': '2022-08-08T00:00:00Z', 'timestamp': 1659916800000}, 'content-version': 'vor', 'delay-in-days': 7, 'URL': 'https://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ {'name': 'Celltrion, Inc'}, {'name': 'Korea Health Technology R&D Project'}, {'name': 'the Korea Health Industry Development Institute'}, {'name': 'Ministry of Health and Welfare, Republic of Korea', 'award': ['HQ20C0073']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2022, 8, 2]]}, 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>We evaluated clinical effectiveness of regdanvimab (CT-P59), a ' 'severe acute respiratory syndrome coronavirus 2 neutralizing monoclonal antibody, in reducing ' 'disease progression and clinical recovery time in patients with mild-to-moderate coronavirus ' 'disease 2019 (COVID-19), primarily Alpha variant.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>This was phase 3 of a phase 2/3 parallel-group, double-blind, ' 'randomized clinical trial. Outpatients with mild-to-moderate COVID-19 were randomized to ' 'single-dose regdanvimab 40\u2005mg/kg (n\u2009=\u2009656) or placebo (n\u2009=\u2009659), ' 'alongside standard of care. The primary endpoint was COVID-19 disease progression up to day ' '28 among “high-risk” patients. Key secondary endpoints were disease progression (all ' 'randomized patients) and time to recovery (high-risk and all randomized patients).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Of 1315 randomized patients, 880 were high risk; the majority were ' 'infected with Alpha variant. The proportion with disease progression was lower (14/446, 3.1% ' '[95% confidence interval {CI}, 1.9%–5.2%] vs 48/434, 11.1% [95% CI, 8.4%–14.4%]; P\u2009' '&amp;lt;\u2009.001) and time to recovery was shorter (median, 9.27 days [95% CI, 8.27–11.05 ' 'days] vs not reached [95% CI, 12.35–not calculable]; P\u2009&amp;lt;\u2009.001) with ' 'regdanvimab than placebo. Consistent improvements were seen in all randomized and ' 'non-high-risk patients who received regdanvimab. Viral load reductions were more rapid with ' 'regdanvimab. Infusion-related reactions occurred in 11 patients (4/652 [0.6%] regdanvimab, ' '7/650 [1.1%] placebo). Treatment-emergent serious adverse events were reported in 5 of (4/652 ' '[0.6%] regdanvimab and 1/650 [0.2%] placebo).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusions</jats:title>\n' ' <jats:p>Regdanvimab was an effective treatment for patients with ' 'mild-to-moderate COVID-19, significantly reducing disease progression and clinical recovery ' 'time without notable safety concerns prior to the emergence of the Omicron variant.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Clinical Trials Registration</jats:title>\n' ' <jats:p>NCT04602000; 2020-003369-20 (EudraCT).</jats:p>\n' ' </jats:sec>', 'DOI': '10.1093/ofid/ofac406', 'type': 'journal-article', 'created': {'date-parts': [[2022, 8, 8]], 'date-time': '2022-08-08T01:17:55Z', 'timestamp': 1659921475000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate ' 'Coronavirus Disease 2019', 'prefix': '10.1093', 'volume': '9', 'author': [ { 'given': 'Jin Yong', 'family': 'Kim', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Internal Medicine, Division of Infectious ' 'Diseases, Incheon Medical Center , Incheon , Republic of ' 'Korea'}]}, { 'given': 'Oana', 'family': 'Săndulescu', 'sequence': 'additional', 'affiliation': [ { 'name': 'National Institute for Infectious Diseases “Prof Dr Matei Balş,” ' 'Carol Davila University of Medicine and Pharmacy , Bucharest , ' 'Romania'}]}, { 'given': 'Liliana-Lucia', 'family': 'Preotescu', 'sequence': 'additional', 'affiliation': [ { 'name': 'National Institute for Infectious Diseases “Prof Dr Matei Balş,” ' 'Carol Davila University of Medicine and Pharmacy , Bucharest , ' 'Romania'}]}, { 'given': 'Norma E', 'family': 'Rivera-Martínez', 'sequence': 'additional', 'affiliation': [{'name': 'Oaxaca Site Management Organization , Oaxaca , Mexico'}]}, { 'given': 'Marta', 'family': 'Dobryanska', 'sequence': 'additional', 'affiliation': [ {'name': 'City Clinical Hospital 12 , Kyiv , Ukraine'}, {'name': 'ARENSIA Exploratory Medicine , Kyiv , Ukraine'}]}, { 'given': 'Victoria', 'family': 'Birlutiu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Faculty of Medicine, Lucian Blaga University of Sibiu, Emergency ' 'Clinical County Hospital , Sibiu , Romania'}]}, { 'given': 'Egidia G', 'family': 'Miftode', 'sequence': 'additional', 'affiliation': [ { 'name': 'Clinical Hospital of Infectious Diseases “Sfanta Parascheva,” ' 'University of Medicine and Pharmacy “Gr. T. Popa,” Iasi , ' 'Romania'}]}, { 'given': 'Natalia', 'family': 'Gaibu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institutul Oncologic din Republica Moldova Republican Clinical ' 'Hospital “T. Moşneaga,” ARENSIA Exploratory Medicine , Chisinau ' ', Moldova'}]}, { 'given': 'Olga', 'family': 'Caliman-Sturdza', 'sequence': 'additional', 'affiliation': [{'name': 'Stefan cel Mare University , Suceava , Romania'}]}, { 'given': 'Simin-Aysel', 'family': 'Florescu', 'sequence': 'additional', 'affiliation': [ { 'name': 'Dr Victor Babes Clinical Hospital for Tropical and Infectious ' 'Diseases , Bucharest , Romania'}]}, { 'given': 'Hye Jin', 'family': 'Shi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine, Division of Infectious ' 'Diseases, Gil Medical Center, Gachon University College of ' 'Medicine , Incheon , Republic of Korea'}]}, { 'given': 'Anca', 'family': 'Streinu-Cercel', 'sequence': 'additional', 'affiliation': [ { 'name': 'National Institute for Infectious Diseases “Prof Dr Matei Balş,” ' 'Carol Davila University of Medicine and Pharmacy , Bucharest , ' 'Romania'}]}, { 'given': 'Adrian', 'family': 'Streinu-Cercel', 'sequence': 'additional', 'affiliation': [ { 'name': 'National Institute for Infectious Diseases “Prof Dr Matei Balş,” ' 'Carol Davila University of Medicine and Pharmacy , Bucharest , ' 'Romania'}]}, { 'given': 'Sang Joon', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Sung Hyun', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Ilsung', 'family': 'Chang', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Yun Ju', 'family': 'Bae', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Jee Hye', 'family': 'Suh', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Da Rae', 'family': 'Chung', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Sun Jung', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Mi Rim', 'family': 'Kim', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Seul Gi', 'family': 'Lee', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Gahee', 'family': 'Park', 'sequence': 'additional', 'affiliation': [{'name': 'Celltrion, Inc , Incheon , Republic of Korea'}]}, { 'given': 'Joong Sik', 'family': 'Eom', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine, Division of Infectious ' 'Diseases, Gil Medical Center, Gachon University College of ' 'Medicine , Incheon , Republic of Korea'}]}], 'member': '286', 'published-online': {'date-parts': [[2022, 8, 8]]}, 'reference': [ { 'key': '2022082916501028800_ofac406-B1', 'doi-asserted-by': 'crossref', 'first-page': '549', 'DOI': '10.1152/physiolgenomics.00089.2020', 'article-title': 'The COVID-19 pandemic: a global health crisis', 'volume': '52', 'author': 'Pollard', 'year': '2020', 'journal-title': 'Physiol Genomics'}, { 'key': '2022082916501028800_ofac406-B2', 'article-title': 'Coronavirus disease (COVID-19) dashboard', 'author': 'World Health Organization'}, { 'key': '2022082916501028800_ofac406-B3', 'article-title': 'Living guidance for clinical management of COVID-19', 'author': 'World Health Organization'}, { 'key': '2022082916501028800_ofac406-B4', 'doi-asserted-by': 'crossref', 'first-page': '238', 'DOI': '10.1056/NEJMoa2035002', 'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with ' 'Covid-19', 'volume': '384', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2022082916501028800_ofac406-B5', 'doi-asserted-by': 'crossref', 'first-page': '229', 'DOI': '10.1056/NEJMoa2029849', 'article-title': 'SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19', 'volume': '384', 'author': 'Chen', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2022082916501028800_ofac406-B6', 'doi-asserted-by': 'crossref', 'first-page': '632', 'DOI': '10.1001/jama.2021.0202', 'article-title': 'Effect of bamlanivimab as monotherapy or in combination with etesevimab ' 'on viral load in patients with mild to moderate COVID-19: a randomized ' 'clinical trial', 'volume': '325', 'author': 'Gottlieb', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': '2022082916501028800_ofac406-B7', 'article-title': 'Hospitalisation risk for Omicron cases in England', 'author': 'Ferguson'}, { 'key': '2022082916501028800_ofac406-B8', 'doi-asserted-by': 'crossref', 'first-page': '959', 'DOI': '10.1016/S1473-3099(22)00141-4', 'article-title': 'Severity of Omicron variant of concern and effectiveness of vaccine ' 'boosters against symptomatic disease in Scotland (EAVE II): a national ' 'cohort study with nested test-negative design', 'volume': '22', 'author': 'Sheikh', 'year': '2022', 'journal-title': 'Lancet Infect Dis'}, { 'key': '2022082916501028800_ofac406-B9', 'doi-asserted-by': 'crossref', 'first-page': '437', 'DOI': '10.1016/S0140-6736(22)00017-4', 'article-title': 'Early assessment of the clinical severity of the SARS-CoV-2 Omicron ' 'variant in South Africa: a data linkage study', 'volume': '399', 'author': 'Wolter', 'year': '2022', 'journal-title': 'Lancet'}, { 'key': '2022082916501028800_ofac406-B10', 'doi-asserted-by': 'crossref', 'first-page': '101455', 'DOI': '10.1016/j.eclinm.2022.101455', 'article-title': 'Severe hospital events following symptomatic infection with SARS-CoV-2 ' 'Omicron and Delta variants in France, December 2021–January 2022: a ' 'retrospective, population-based, matched cohort study', 'volume': '48', 'author': 'Auvigne', 'year': '2022', 'journal-title': 'EClinicalMedicine'}, { 'key': '2022082916501028800_ofac406-B11', 'doi-asserted-by': 'crossref', 'first-page': '564', 'DOI': '10.1111/tmi.13752', 'article-title': 'Outcomes of laboratory-confirmed SARS-CoV-2 infection in the ' 'Omicron-driven fourth wave compared with previous waves in the Western ' 'Cape Province, South Africa', 'volume': '27', 'author': 'Davies', 'year': '2022', 'journal-title': 'Trop Med Int Health'}, { 'key': '2022082916501028800_ofac406-B12', 'doi-asserted-by': 'crossref', 'first-page': '671', 'DOI': '10.1038/s41586-021-04389-z', 'article-title': 'Considerable escape of SARS-CoV-2 Omicron to antibody neutralization', 'volume': '602', 'author': 'Planas', 'year': '2022', 'journal-title': 'Nature'}, { 'key': '2022082916501028800_ofac406-B13', 'doi-asserted-by': 'publisher', 'article-title': 'Molecular basis of broad neutralization against SARS-CoV-2 variants ' 'including Omicron by a human antibody', 'volume-title': 'bioRxiv', 'author': 'Ju', 'DOI': '10.1101/2022.01.19.476892'}, { 'key': '2022082916501028800_ofac406-B14', 'doi-asserted-by': 'crossref', 'first-page': '970', 'DOI': '10.1002/eji.202249841', 'article-title': 'Augmented neutralization of SARS-CoV-2 Omicron variant by boost ' 'vaccination and monoclonal antibodies', 'volume': '52', 'author': 'Schulz', 'year': '2022', 'journal-title': 'Eur J Immunol'}, { 'key': '2022082916501028800_ofac406-B15', 'doi-asserted-by': 'crossref', 'first-page': '288', 'DOI': '10.1038/s41467-020-20602-5', 'article-title': 'A therapeutic neutralizing antibody targeting receptor binding domain ' 'of SARS-CoV-2 spike protein', 'volume': '12', 'author': 'Kim', 'year': '2021', 'journal-title': 'Nat Commun'}, { 'key': '2022082916501028800_ofac406-B16', 'article-title': 'Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab ' '(CT-P59) becomes the first authorized COVID-19 treatment approved from ' 'the Korean Ministry of Food and Drug Safety (MFDS)', 'author': 'Business Wire'}, { 'key': '2022082916501028800_ofac406-B17', 'article-title': 'Regkirona (regdanvimab)', 'author': 'European Medicines Agency'}, { 'key': '2022082916501028800_ofac406-B18', 'doi-asserted-by': 'crossref', 'first-page': '1706', 'DOI': '10.1016/j.clinthera.2021.08.009', 'article-title': 'Safety, virologic efficacy, and pharmacokinetics of CT-P59, a ' 'neutralizing monoclonal antibody against SARS-CoV-2 spike ' 'receptor-binding protein: two randomized, placebo-controlled, phase I ' 'studies in healthy individuals and patients with mild SARS-CoV-2 ' 'infection', 'volume': '43', 'author': 'Kim', 'year': '2021', 'journal-title': 'Clin Ther'}, { 'key': '2022082916501028800_ofac406-B19', 'doi-asserted-by': 'crossref', 'first-page': 'ofac053', 'DOI': '10.1093/ofid/ofac053', 'article-title': 'Efficacy and safety of regdanvimab (CT-P59): a phase 2/3 randomized, ' 'double-blind, placebo-controlled trial in outpatients with ' 'mild-to-moderate coronavirus disease 2019', 'volume': '9', 'author': 'Streinu-Cercel', 'year': '2022', 'journal-title': 'Open Forum Infect Dis'}, { 'key': '2022082916501028800_ofac406-B20', 'doi-asserted-by': 'publisher', 'article-title': 'Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal ' 'antibodies', 'volume-title': 'bioRxiv', 'author': 'Yamasoba', 'DOI': '10.1101/2022.07.14.500041'}, { 'key': '2022082916501028800_ofac406-B21', 'doi-asserted-by': 'crossref', 'first-page': '4048', 'DOI': '10.1038/s41467-021-24339-7', 'article-title': 'CVnCov and CV2CoV protect human ACE2 transgenic mice from ancestral B ' 'BavPat1 and emerging B.1.351 SARS-CoV-2', 'volume': '12', 'author': 'Hoffmann', 'year': '2021', 'journal-title': 'Nat Commun'}, { 'key': '2022082916501028800_ofac406-B22', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/s12979-020-00212-x', 'article-title': 'Obesity and COVID-19: what makes obese host so vulnerable?', 'volume': '18', 'author': 'Mohammad', 'year': '2021', 'journal-title': 'Immun Ageing'}, { 'key': '2022082916501028800_ofac406-B23', 'doi-asserted-by': 'crossref', 'first-page': 'e3377', 'DOI': '10.1002/dmrr.3377', 'article-title': 'Obesity and diabetes as high-risk factors for severe coronavirus ' 'disease 2019 (Covid-19)', 'volume': '37', 'author': 'Zhou', 'year': '2021', 'journal-title': 'Diabetes Metab Res Rev'}, { 'key': '2022082916501028800_ofac406-B24', 'doi-asserted-by': 'crossref', 'first-page': '24', 'DOI': '10.1016/j.pcd.2020.08.015', 'article-title': 'Diabetes and COVID-19: a pooled analysis related to disease severity ' 'and mortality', 'volume': '15', 'author': 'Varikasuvu', 'year': '2021', 'journal-title': 'Prim Care Diabetes'}, { 'key': '2022082916501028800_ofac406-B25', 'article-title': 'American College of Cardiology. Mitigating ASCVD risk among those ' 'previously infected with COVID-19', 'author': 'Naz'}, { 'key': '2022082916501028800_ofac406-B26', 'article-title': 'COVID-19 risk factors and risk groups', 'author': 'European Centre for Disease Prevention and Control'}, { 'key': '2022082916501028800_ofac406-B27', 'doi-asserted-by': 'crossref', 'first-page': '1382', 'DOI': '10.1056/NEJMoa2102685', 'article-title': 'Bamlanivimab plus etesevimab in mild or moderate Covid-19', 'volume': '385', 'author': 'Dougan', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2022082916501028800_ofac406-B28', 'doi-asserted-by': 'crossref', 'first-page': 'e81', 'DOI': '10.1056/NEJMoa2108163', 'article-title': 'REGEN-COV antibody combination and outcomes in outpatients with ' 'Covid-19', 'volume': '385', 'author': 'Weinreich', 'year': '2021', 'journal-title': 'N Engl J Med'}, { 'key': '2022082916501028800_ofac406-B29', 'article-title': 'Tracking of variants: VOC Delta, relative variant genome frequency per ' 'region', 'author': 'GISAID'}, { 'key': '2022082916501028800_ofac406-B30', 'doi-asserted-by': 'crossref', 'first-page': 'e040380', 'DOI': '10.1136/bmjopen-2020-040380', 'article-title': 'Temporal profile and determinants of viral shedding and of viral ' 'clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive ' 'subjects: a population-based prospective cohort study in Reggio Emilia, ' 'Italy', 'volume': '10', 'author': 'Mancuso', 'year': '2020', 'journal-title': 'BMJ Open'}, { 'key': '2022082916501028800_ofac406-B31', 'doi-asserted-by': 'crossref', 'first-page': '772320', 'DOI': '10.3389/fimmu.2021.772320', 'article-title': 'Effectiveness of regdanvimab treatment in high-risk COVID-19 patients ' 'to prevent progression to severe disease', 'volume': '12', 'author': 'Lee', 'year': '2021', 'journal-title': 'Front Immunol'}, { 'key': '2022082916501028800_ofac406-B32', 'doi-asserted-by': 'crossref', 'first-page': '135', 'DOI': '10.1016/j.bbrc.2021.06.016', 'article-title': 'Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant', 'volume': '566', 'author': 'Ryu', 'year': '2021', 'journal-title': 'Biochem Biophys Res Commun'}, { 'key': '2022082916501028800_ofac406-B33', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1016/j.bbrc.2021.09.023', 'article-title': 'The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and ' 'its associated variants of SARS-CoV-2', 'volume': '578', 'author': 'Ryu', 'year': '2021', 'journal-title': 'Biochem Biophys Res Commun'}, { 'key': '2022082916501028800_ofac406-B34', 'doi-asserted-by': 'crossref', 'first-page': 'e040638', 'DOI': '10.1136/bmjopen-2020-040638', 'article-title': 'Deaths in people from Black, Asian and minority ethnic communities from ' 'both COVID-19 and non-COVID causes in the first weeks of the pandemic ' 'in London: a hospital case note review', 'volume': '10', 'author': 'Perkin', 'year': '2020', 'journal-title': 'BMJ Open'}, { 'key': '2022082916501028800_ofac406-B35', 'doi-asserted-by': 'crossref', 'first-page': '117', 'DOI': '10.1007/s40615-020-00934-0', 'article-title': 'Age, comorbid conditions, and racial disparities in COVID-19 outcomes', 'volume': '9', 'author': 'Wiley', 'year': '2022', 'journal-title': 'J Racial Ethn Health Disparities'}, { 'key': '2022082916501028800_ofac406-B36', 'doi-asserted-by': 'crossref', 'first-page': '46', 'DOI': '10.1016/j.annepidem.2020.07.007', 'article-title': 'Risk for COVID-19 infection and death among Latinos in the United ' 'States: examining heterogeneity in transmission dynamics', 'volume': '52', 'author': 'Rodriguez-Diaz', 'year': '2020', 'journal-title': 'Ann Epidemiol'}, { 'key': '2022082916501028800_ofac406-B37', 'doi-asserted-by': 'crossref', 'first-page': '382', 'DOI': '10.1038/s41577-021-00542-x', 'article-title': 'Neutralizing monoclonal antibodies for treatment of COVID-19', 'volume': '21', 'author': 'Taylor', 'year': '2021', 'journal-title': 'Nat Rev Immunol'}, { 'key': '2022082916501028800_ofac406-B38', 'doi-asserted-by': 'crossref', 'first-page': '1469', 'DOI': '10.1056/NEJMp1802256', 'article-title': 'Monoclonal antibodies for emerging infectious diseases—borrowing from ' 'history', 'volume': '378', 'author': 'Marston', 'year': '2018', 'journal-title': 'N Engl J Med'}, { 'key': '2022082916501028800_ofac406-B39', 'article-title': 'Coronavirus-19 (COVID-19): Covid-19 vaccination and domestic outbreaks ' '(2.4.) [in Korean]', 'author': 'Ministry of Health and Welfare'}], 'container-title': 'Open Forum Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac406/45287239/ofac406.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/ofid/article-pdf/9/8/ofac406/45612082/ofac406.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/ofid/article-pdf/9/8/ofac406/45612082/ofac406.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 8, 29]], 'date-time': '2022-08-29T16:51:19Z', 'timestamp': 1661791879000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofac406/6657716'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 8, 1]]}, 'references-count': 39, 'journal-issue': {'issue': '8', 'published-print': {'date-parts': [[2022, 8, 2]]}}, 'URL': 'http://dx.doi.org/10.1093/ofid/ofac406', 'relation': {}, 'ISSN': ['2328-8957'], 'subject': ['Infectious Diseases', 'Oncology'], 'published-other': {'date-parts': [[2022, 8, 1]]}, 'published': {'date-parts': [[2022, 8, 1]]}}